Because there is evidence for an active immunologic response against sarcoma, a clinical trial of adjuvant immunotherapy using BCG and tumor cell vaccine was begun. Of 18 patients with localized soft tissue sarcoma who received immunotherapy, 11 are free of disease, compared to only 5 of 15 treated by operation alone who are free of disease. Immunotherapy also prolonged the median disease-free interval from 7.3-15 mo. in the patients who experienced recurrence of their disease.